The primary outcome results for the SPS3 trial suggested that a lower systolic target blood pressure ( < 130 mm Hg ) might be beneficial for reducing the risk of recurrent stroke compared with a higher target ( 130-149 mm Hg ) , but that the addition of clopidogrel to aspirin was not beneficial compared with aspirin plus placebo .